Century Therapeutics (IPSC) Research & Development (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Research & Development data on file, last reported at $17.1 million in Q1 2026.

• Research & Development for Q1 2026 came in at $17.1 million, down 35.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.2 million (down 21.94% YoY), and the FY2025 annual result was $95.7 million, down 10.8% from the prior year.
• Research & Development fell to $17.1 million in Q1 2026 per IPSC's latest filing, from $19.7 million in the prior quarter.
• Over five years, Research & Development peaked at $29.4 million in Q4 2024 and troughed at $17.1 million in Q1 2026.
• A 5-year average of $24.1 million and a median of $24.5 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2026: Research & Development soared 37.87% in 2022, then slumped 35.65% in 2026.
• A 5-year view of Research & Development shows it stood at $25.6 million in 2022, then decreased by 12.86% to $22.3 million in 2023, then jumped by 31.75% to $29.4 million in 2024, then sank by 32.95% to $19.7 million in 2025, then fell by 13.15% to $17.1 million in 2026.
• Business Quant data shows IPSC's Research & Development at $17.1 million in Q1 2026, $19.7 million in Q4 2025, and $22.5 million in Q3 2025.